Skip to content

Key Facts and History


Founded: 1960
Exchange/Ticker: NYSE: VRX
Worldwide Employees: approximately 2,300
Corporate Headquarters: Aliso Viejo, California

2008 Revenues: $657 million
$593.2 million from product sales
$63.8 million from alliance revenue

2007 Revenues: $872.2 million
$785.8 million from product sales
$86.5 million from ribavirin royalties

Snapshot


  • Multinational specialty pharmaceutical company
  • Diverse product portfolio with focus on branded pharmaceuticals, branded generics and over-the-counter
  • Specialization in neurology and dermatology
  • Product sales with focus on North America, Central Europe, Mexico, Brazil, and Australia
  • Development capability
  • Manufacturing sites in Canada, Brazil, Poland and Mexico
  • Regulatory and medical expertise

Pipeline


  • Retigabine - Positive data from RESTORE Phase III clinical trials for the treatment of epileptic seizures
  • Taribavirin - Currently in Phase 2b clinical trials for the treatment of hepatitis C (HCV)
  • Dermatology compounds IDP 115 (Rosacea), IDP 107 (Acne), IDP108 and IDP113 (Topical Anti-Fungals)

History


2008
  • Valeant acquires Dow Pharmaceutical Sciences, Inc.
  • Valeant acquires Dermatech
  • Valeant acquires Coria laboratories, Ltd.
  • Valeant and GlaxoSmithKline announce worldwide collaboration agreement for retigabine
  • Valeant enters into joint venture with Meda AB
  • Valeant sells certain business operations in Europe for $392 million
  • Valeant successfully completes retigabine Phase III epilepsy program validating novel mechanism of action
  • Valeant names J. Michael Pearson as Chairman and Chief Executive Officer
2007
  • Valeant signs licensing agreement for Canadian rights to (C)Xyrem® from Jazz Pharmaceuticals
  • Valeant initiates taribavirin Phase 2b clinical study
  • Valeant initiates study of retigabine for pain associated with post-herpetic neuralgia
  • Valeant launches Bedoyecta in the United States
  • Valeant sells Hepatitis-C drug Infergen® to Three Rivers Pharmaceuticals®, LLC
2006
  • Valeant receives FDA approval of Zelapar® for patients with Parkinson's Disease
  • Valeant obtains FDA marketing approval for Cesamet™ to treat nausea and vomiting associated with cancer chemotherapy
  • Kinerase® skincare line is extended and distribution through Nordstrom is launched
  • Valeant launches Zelapar® in the United States for Parkinson's disease
  • Valeant launches Cesamet® in the United States
  • Valeant's worldwide headquarters relocates to Aliso Viejo, California
  • Valeant sells discovery and preclinical assets to Ardea Biosciences
2005
  • Valeant initiates Phase 3 clinical trials for its epilepsy candidate retigabine
  • Valeant signs agreement with actress Courteney Cox to represent Kinerase® and distributes line to high-end retailer Sephora
  • Valeant acquires Xcel Pharmaceuticals, expanding Valeant's neurology franchise to include Migranal®, Diastat® and epilepsy treatment candidate retigabine
  • Valeant unveils Diastat® AcuDial™ for rapid, at-home treatment of epileptic seizures
  • Valeant completes public offering of 7.2 million shares
  • Timothy T. Tyson appointed President and Chief Executive Officer
2004
  • Valeant acquires Amarin Pharmaceuticals, Inc., expanding its specialty neurology platform with Zelapar™
  • Valeant acquires global rights to Tasmar®, further building the company's specialty neurology platform
2003
  • ICN and Ribapharm settle litigation with F. Hoffman La-Roche (Roche), which results in licensing the sale of ribavirin to Roche
  • ICN completes the sale of Photonics and Circe units
  • ICN completes the sale of its Russian manufacturing and retail pharmacy operations for $55 million
  • ICN completes the reacquisition of the 20 percent minority interest in Ribapharm, and merges Ribapharm into ICN operations
  • ICN sells Personal Radiation Dosimetry Division to Global Dosimetry Solutions, Inc. for $58 million
  • ICN announces its first direct-to-consumer marketing campaign for Kinerase®
  • ICN changes its name to Valeant Pharmaceuticals International (NYSE:VRX), signifying the core principles and values underpinning the company and its new strategic focus
2002
  • ICN issues IPO for approximately 20 percent interest in subsidiary, Ribapharm Inc.
  • Robert W. O'Leary named Chief Executive Officer and Chairman of the Board of Directors
  • ICN divests operations in Russia, Hungary and Czech Republic, its Biomedicals subsidiary, Photonics business in North America and the Circe unit
  • ICN institutes several new corporate governance initiatives that increase transparency, establish greater Board independence and change the way the company does business
1970-2001
  • Schering-Plough announces FDA approval to market ICN's drug, ribavirin, as REBETOL® capsules for use in combination with PEG-INTRON for chronic hepatitis C
  • Shareholders vote to merge ICN Pharmaceuticals, ICN Biomedicals, SPI Pharmaceuticals and Viratek, Inc. into a single worldwide pharmaceutical company - ICN Pharmaceuticals, Inc.
  • ICN Plaza in Costa Mesa, CA., becomes ICN's international headquarters
  • Sales exceed $100 million as ICN received its first FDA approval for L-dopa
  • Stock trades for the first time on the New York Stock Exchange
  • Major product, ribavirin, is discovered in ICN labs

1960: ICN Pharmaceuticals, Inc. is founded as International Chemical and Nuclear Corporation